Where does Decima Spine, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Decima Spine, Inc. ranks #39,776 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Decima Spine, Inc. hold?

Decima Spine, Inc. holds 6 US utility patents granted between 2016 and 2020, spanning 1 technology areas.

What is Decima Spine, Inc.'s Innovation Score?

Decima Spine, Inc. has an Innovation Score of 20.4 out of 100 (7th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Decima Spine, Inc. focus on?

Decima Spine, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 6 patents, ranking #2,680 of 7,127 assignees active in that subclass. Grants appear in 1 CPC subclasses total.

Is Decima Spine, Inc.'s patent grant rate increasing or decreasing?

Decima Spine, Inc.'s recent grant velocity is -50% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Decima Spine, Inc.'s patents?

Decima Spine, Inc.'s patents average 16.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Decima Spine, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Decima Spine, Inc.

USPTO PatentsView assignee record - 6 granted patents across 1 technology areas, recorded in grant years 2016–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Decima ranks #39,776 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 1 technology areas.

#39,776
of 49,997 US assignees by volume: 7th percentile
by Innovation Score (20.4/100): 16.8
avg claims per patent: -50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R39776 · US Corporation #39,776 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #39,776/49,997
PHOTO-FINISH De La Rue North…
CPC-NARROW A61B · 1 areas
INNOV-THIN 20.4/100
CLAIMS-RICH 16.8 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: De La Rue North America Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Decima’s 20.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (33%) Velocity 0.0 pts (0%) Breadth 3.5 pts (17%) Claim depth 10.1 pts (50%)

Qualcomm Incorporated · highest

85
Decima Spine · this assignee

20
3D Lighting… · lowest

7

What this shows Decima's Innovation Score is 20.4/100 (7th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Decima?

Each dot is one of Decima’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Decima’s own 16.8 claims/patent is ABOVE the 15.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Decima vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Decima's grants concentrate

Decima Spine, Inc. is a focused PatentsView assignee: 1 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). By volume, Decima sits between De La Rue North America Inc. and DeepTruth, LLC.

De La Rue North A…

6
De Nora Water

6
Degirum

6
Dechra Veterinary…

6
Decoma (Germany)

6
Deep Vein Medical

6
Deepsight Technol…

6
Deeptruth

6
Decima Spine ◀

6

What this shows Decima holds 6 patents at rank #39,836, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Decima

By rank, the assignees closest to #39,836 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Decima's primary technology class.

Decima's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

20 7th percentile higher than 7% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Decima Spine, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	33.3%
2018	2	33.3%
2020	2	33.3%

Which technologies does Decima Spine, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 6

Top 1 of 1 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Decima Spine, Inc.'s patent record in context - here's where to go next.

Decima Spine, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 100% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #39,776 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Decima Spine, Inc. against De La Rue North America Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 20.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.